Related Experiment Video
Updated: Jul 10, 2026

Autologous Blood Injection to Model Spontaneous Intracerebral Hemorrhage in Mice
Published on: August 24, 2011
TRPC3 Mediates Neurological Dysfunction after Intracerebral Hemorrhage in Mice
Kosei Tamada1, Shota Tobori1, Nozomi Kato1
1Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Insights
Transient Receptor Potential Canonical 3 (TRPC3) channels contribute to brain damage after intracerebral hemorrhage (ICH). Targeting TRPC3 may offer a new therapeutic strategy for stroke recovery.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- Intracerebral hemorrhage (ICH) causes secondary brain injury via pathological intracellular calcium (Ca2+) signaling.
- Common downstream pathways, like TRPC3 channels, may be better therapeutic targets than individual receptors.
Purpose of the Study:
- Investigate the role of TRPC3 channels in neurological dysfunction following ICH.
- Utilize TRPC3 knockout mice and astrocyte-specific knockdown models.
Main Methods:
- Generated TRPC3 knockout (KO) mice.
- Administered astrocyte-specific TRPC3 knockdown using adeno-associated virus vectors.
- Assessed neurological deficit scores and rotarod performance post-ICH.
Main Results:
- TRPC3-KO mice showed significantly reduced neurological deficits and improved motor function after ICH.
- Astrocyte-specific TRPC3 knockdown did not significantly improve neurological outcomes.
- These findings suggest TRPC3 contributes to ICH-induced dysfunction, involving multiple cell types.
Conclusions:
- TRPC3 channels play a critical role in neurological impairment after ICH.
- Pathological TRPC3 function involves more than just astrocytes.
- TRPC3 inhibition presents a potential therapeutic avenue for mitigating ICH-related neurological damage.
Abstract:
Intracerebral hemorrhage (ICH) is a lethal stroke subtype characterized by secondary injury resulting from pathological intracellular Ca2+ signaling. Bioactive molecules such as ATP and thrombin activate multiple receptor subtypes. Thus, targeting a common downstream molecular mechanism may be more effective than inhibiting individual receptors. One potential candidate is transient receptor potential canonical 3 (TRPC3), a Ca2+-permeable nonselective cation channel activated via Gq/phospholipase C signaling. However, its role in ICH remains unclear. Thus, this study aimed to investigate the role of TRPC3 in neurological dysfunction after ICH by using TRPC3 knockout (KO) mice and astrocyte-specific knockdown approaches. The TRPC3-KO mice exhibited significantly lower neurological deficit scores and performed better on the rotarod test than the wild-type mice at 1 and 3 d after ICH, suggesting that TRPC3 plays a critical role in functional impairment. However, the astrocyte-specific knockdown of TRPC3 using an adeno-associated virus vector did not significantly improve neurological dysfunction. These results indicate that TRPC3 contributes to neurological dysfunction after ICH, but that its pathological role cannot be explained by astrocytic TRPC3 alone, indicating the involvement of multiple cell types. In conclusion, TRPC3 is a key channel involved in neurological dysfunction after ICH, suggesting that targeting TRPC3 may provide a new therapeutic strategy for attenuation of neurological dysfunction after ICH.

